Market Cap
$2.9B
NAMS
NewAmsterdam Pharma Co N.V.
$23.08 ▼ -4.47%
Prev close $24.16Market cap$2.9B
ConsensusStrong Buy
12-mo target$50.36 (+118.2%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on NAMS right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (91%)
Insider Activity
$226.5K buy / $45.0M sell
Insider Net $
-$44.7M
SEC Reports
4
Price chart 30d -9.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Sep 16, 2026 SEC Short Volume: NAMS — 55.2% short (0.4M / 0.7M)
Short: 389,660 | Exempt: 0 | TRF Vol: 706,115 | Short Ratio: 55.2% | Off-exchange volume (dark pool
CEO Michael Davidson purchased $227K of NAMS stock on the open market at $22.65/share, a standalone conviction buy. This
INSIDER-BUY — Impact 5/10
Sep 14, 2026 Insider
Davidson Michael H. bought 10,000 shares
Chief Executive Officer @ $22.65 ($226.5K)
Sep 4, 2026 Insider
Smither John W sold 1,600 shares
Director @ $25.32 ($40.5K)
Sep 1, 2026 Insider
Aug 5, 2026 SEC Gunning Robert William was granted 14,000 shares
Vice President, Controller
NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a positive opinion rec
8-K — Impact 7/10
NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending marketing authorization fo
8-K — Impact 7/10
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 6, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jun 30, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 12 | 2 | 0 | 0 | 91% | |
| Aug 1, 2026 | 9 | 12 | 2 | 0 | 0 | 91% | |
| Jul 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% |
Price targets
Where 15 covering analysts think NAMS trades over the next 12 months.
$50.36 +118.2% upside Strong Buy
Current$23.08 Low$37.06 Median$50.45 High$59.63 15 analysts
$37.06$59.63
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 6.0/10.
BULLISHINSIDER-BUY5/10
CEO Michael Davidson purchased $227K of NAMS stock on the open market at $22.65/share, a standalone
Sep 16, 2026
BULLISH8-K7/10
NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a
Aug 5, 2026
BULLISH8-K7/10
NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending market
Jul 24, 2026
NEUTRALPRESS-RELEASE5/10
{ "summary": "NewAmsterdam Pharma issued a press release announcing participation in an upcoming i
Apr 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: NAMS — 55.2% short (0.4M / 0.7M)
Short: 389,660 | Exempt: 0 | TRF Vol: 706,115 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: NAMS — 60.2% short (0.5M / 0.8M)
Short: 456,135 | Exempt: 0 | TRF Vol: 757,626 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
other
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerab
Sep 18, 2026
short_volume
Short Volume: NAMS — 61.2% short (0.6M / 0.9M)
Short: 560,491 | Exempt: 0 | TRF Vol: 915,589 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: NAMS — 64.8% short (0.7M / 1.0M)
Short: 677,388 | Exempt: 0 | TRF Vol: 1,045,322 | Short Ratio: 64.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.43 | $-0.54–$-0.29 | 18.4% | +2.6% | 0↑ 7↓ | $0.0B | 13 |
| Next Q | $-0.39 | $-0.55–$-0.23 | 26.3% | +1.1% | 3↑ 3↓ | $0.0B | 13 |
| Current FY | $-1.65 | $-1.87–$-1.43 | -13.5% | +0.2% | 1↑ 7↓ | $0.0B | 12 |
| Next FY | $-1.55 | $-2.74–$1.88 | 5.8% | -0.8% | 2↑ 4↓ | $0.1B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.434 | — |
| 7d ago | $-0.445 | +0.011 |
| 30d ago | $-0.446 | +0.012 |
| 60d ago | $-0.422 | -0.012 |
| 90d ago | $-0.420 | -0.014 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 41 transactions. Net -$44.7M — $226.5K bought, $45.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Davidson Michael H. | Chief Executive Officer | BUY | 10,000 | $22.65 | $226.5K |
| Sep 4, 2026 | Smither John W | Director | SELL | 1,600 | $25.32 | $40.5K |
| Sep 1, 2026 | Gunning Robert William | Vice President, Controller | AWARD | 14,000 | — | — |
| Sep 1, 2026 | Gunning Robert William | Vice President, Controller | AWARD | 3,200 | — | — |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | EXERCISE | 80,000 | $11.17 | $893.6K |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | EXERCISE | 25,000 | $11.90 | $297.5K |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | SELL | 31,885 | $31.05 | $990.0K |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | SELL | 70,200 | $29.96 | $2.1M |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | SELL | 2,915 | $31.71 | $92.4K |
| Jun 22, 2026 | Kooij Louise Frederika | Chief Accounting Officer | EXERCISE | 25,000 | $10.90 | $272.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NAMS.
Shares short
15,660,444
Settlement Sep 15, 2026
Change vs prior
+16.9%
Semi-monthly cycle
Days to cover
9.9
At avg daily volume
Of shares outstanding
≈13.1%
Estimate — not % of float
All NAMS filing & press-release reports (4)
- INSIDER-BUY reportSep 16, 2026
- 8-K reportAug 5, 2026
- 8-K reportJul 24, 2026
- PRESS-RELEASE reportApr 8, 2026